Evogene Q2 net loss narrows to USD 1.8 million; revenue slips to USD 0.3 million

Reuters2026/08/18 11:04

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Evogene posted a Q2 net loss of USD 1.8 million, narrowing from USD 4.7 million a year earlier.
Q2 revenue slipped to USD 0.3 million from USD 0.5 million, mainly on the conclusion of AgPlenus’ Bayer agreement in May 2026.
Cash and cash equivalents totaled USD 9.3 million at June 30, with Q2 cash usage of about USD 2.1 million.
Full-year 2026 cash usage forecast at USD 8.5 million-USD 9.5 million, down from about USD 14.4 million in 2025.
Operationally, six active drug collaborations; virtual chemical space expanded to about 110 billion molecules, supported by AI Agents and new models.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evogene Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178913-26-004174), on August 18, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Evogene Q2 net loss narrows to USD 1.8 million; revenue slips to USD 0.3 million

You may also like

Crypto prices